Chimerix Inc. (NASDAQ:CMRX) shares traded down 3.8% on Thursday . The company traded as low as $4.01 and last traded at $4.02, with a volume of 247,170 shares trading hands. The stock had previously closed at $4.18.

A number of research analysts have recently weighed in on the company. FBR & Co reaffirmed a “hold” rating on shares of Chimerix in a research report on Sunday, July 17th. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $16.98.

The company’s market cap is $184.39 million. The firm’s 50-day moving average is $3.93 and its 200-day moving average is $5.34.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.09. The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $2.79 million. On average, analysts forecast that Chimerix Inc. will post ($2.06) earnings per share for the current year.

In other Chimerix news, CEO M Michelle Berrey purchased 13,188 shares of the stock in a transaction on Friday, June 24th. The shares were bought at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the completion of the transaction, the chief executive officer now owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario purchased 25,000 shares of the stock in a transaction on Wednesday, May 11th. The shares were acquired at an average price of $4.85 per share, for a total transaction of $121,250.00. Following the transaction, the director now directly owns 297,240 shares of the company’s stock, valued at approximately $1,441,614. The disclosure for this purchase can be found here.

A number of institutional investors have modified their holdings of CMRX. Jennison Associates LLC increased its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares in the last quarter. Trexquant Investment LP increased its position in Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares during the period. Finally, Morgan Stanley increased its position in Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares during the period.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.